TWI580430B - 用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽 - Google Patents

用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽 Download PDF

Info

Publication number
TWI580430B
TWI580430B TW100139078A TW100139078A TWI580430B TW I580430 B TWI580430 B TW I580430B TW 100139078 A TW100139078 A TW 100139078A TW 100139078 A TW100139078 A TW 100139078A TW I580430 B TWI580430 B TW I580430B
Authority
TW
Taiwan
Prior art keywords
peptide
fviii
amino acid
amino acids
seq
Prior art date
Application number
TW100139078A
Other languages
English (en)
Chinese (zh)
Other versions
TW201231065A (en
Inventor
卡塔琳娜 諾拉 史坦尼茲
海登 寶拉 瑪莉亞 威爾漢密娜 凡
伯吉特 瑪莉亞 瑞伯特
漢斯 彼得 史瓦茲
哈穆 赫里基
Original Assignee
巴克斯歐塔公司
巴克斯歐塔有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 巴克斯歐塔公司, 巴克斯歐塔有限公司 filed Critical 巴克斯歐塔公司
Publication of TW201231065A publication Critical patent/TW201231065A/zh
Application granted granted Critical
Publication of TWI580430B publication Critical patent/TWI580430B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
TW100139078A 2010-10-27 2011-10-27 用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽 TWI580430B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40740210P 2010-10-27 2010-10-27
US201161467894P 2011-03-25 2011-03-25
US201161502476P 2011-06-29 2011-06-29

Publications (2)

Publication Number Publication Date
TW201231065A TW201231065A (en) 2012-08-01
TWI580430B true TWI580430B (zh) 2017-05-01

Family

ID=45349271

Family Applications (3)

Application Number Title Priority Date Filing Date
TW100139078A TWI580430B (zh) 2010-10-27 2011-10-27 用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽
TW106113613A TW201730205A (zh) 2010-10-27 2011-10-27 用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽
TW105138248A TW201708251A (zh) 2010-10-27 2011-10-27 用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW106113613A TW201730205A (zh) 2010-10-27 2011-10-27 用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽
TW105138248A TW201708251A (zh) 2010-10-27 2011-10-27 用於免疫耐受誘導及免疫診斷之ｆｖｉｉｉ胜肽

Country Status (20)

Country Link
US (3) US8969524B2 (enExample)
EP (2) EP3260132B1 (enExample)
JP (2) JP6122780B2 (enExample)
KR (2) KR102222864B1 (enExample)
CN (2) CN103298482B (enExample)
AR (1) AR083586A1 (enExample)
AU (2) AU2011319747C1 (enExample)
BR (1) BR112013010362A2 (enExample)
CA (1) CA2815239C (enExample)
DK (1) DK2632479T3 (enExample)
EA (1) EA034494B1 (enExample)
ES (2) ES2639039T3 (enExample)
HK (1) HK1215442A1 (enExample)
MX (1) MX347805B (enExample)
NZ (2) NZ703514A (enExample)
PL (2) PL2632479T3 (enExample)
PT (1) PT2632479T (enExample)
SG (2) SG189914A1 (enExample)
TW (3) TWI580430B (enExample)
WO (1) WO2012058480A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006063031A2 (en) 2004-12-06 2006-06-15 Haplomics Allelic variants of human factor viii
PL2917232T3 (pl) * 2012-11-12 2017-09-29 Apitope International Nv Pochodzące od czynnika VIII peptydy do zastosowania w leczeniu hemofilii A
US10272163B2 (en) 2012-12-07 2019-04-30 The Regents Of The University Of California Factor VIII mutation repair and tolerance induction
US20160038575A1 (en) * 2013-03-15 2016-02-11 Haplomics, Inc. Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a
WO2017180807A1 (en) 2016-04-15 2017-10-19 Baxalta Incorporated Method and apparatus for providing a pharmacokinetic drug dosing regiment
US20170128544A1 (en) * 2014-06-12 2017-05-11 University Of Hawaii Uses of Humanized Cobra Venom Factor for Reducing or Preventing Immunogenicity
WO2016120218A1 (en) * 2015-01-26 2016-08-04 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256304A1 (en) * 2002-04-18 2005-11-17 Tim Jones Modified factor VIII

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485314B2 (en) * 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
ATE427499T1 (de) * 2004-05-21 2009-04-15 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
SI2522717T1 (sl) 2006-01-04 2014-05-30 Baxter International Inc. Mediji celične kulture brez oligopeptidov
GB0723712D0 (en) 2007-12-04 2008-01-16 Apitope Technology Bristol Ltd Peptides
US7673687B2 (en) 2007-12-05 2010-03-09 Halliburton Energy Services, Inc. Cement compositions comprising crystalline organic materials and methods of using same
DE202007017320U1 (de) 2007-12-07 2008-02-28 Dittmann, Ludwig Vorrichtung zur Raumbeduftung
GB0801513D0 (en) * 2008-01-28 2008-03-05 Circassia Ltd Peptides from factor VIII
WO2009099991A2 (en) 2008-01-31 2009-08-13 The Brigham And Women's Hospital, Inc. Treatment of cancer
EP2385825B1 (en) 2008-11-07 2018-10-10 University of Connecticut Factor viii formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050256304A1 (en) * 2002-04-18 2005-11-17 Tim Jones Modified factor VIII

Also Published As

Publication number Publication date
ES2912455T3 (es) 2022-05-26
JP6122780B2 (ja) 2017-04-26
AU2011319747C1 (en) 2016-07-14
TW201708251A (zh) 2017-03-01
EP3260132B1 (en) 2022-02-09
PL2632479T3 (pl) 2017-09-29
US20120135019A1 (en) 2012-05-31
MX2013004753A (es) 2013-09-13
SG189914A1 (en) 2013-06-28
NZ703514A (en) 2017-02-24
JP2014505014A (ja) 2014-02-27
EA201390617A1 (ru) 2013-10-30
CA2815239A1 (en) 2012-05-03
US9512198B2 (en) 2016-12-06
HK1215442A1 (zh) 2016-08-26
SG10201600656WA (en) 2016-02-26
MX347805B (es) 2017-05-15
AU2011319747B2 (en) 2016-01-07
AU2011319747A1 (en) 2013-05-02
CA2815239C (en) 2019-02-26
AR083586A1 (es) 2013-03-06
CN103298482A (zh) 2013-09-11
CN104926947A (zh) 2015-09-23
TW201231065A (en) 2012-08-01
US20150203567A1 (en) 2015-07-23
AU2016202155B2 (en) 2018-02-01
PL3260132T3 (pl) 2022-08-08
KR102222864B1 (ko) 2021-03-04
AU2016202155A1 (en) 2016-04-28
EA034494B1 (ru) 2020-02-13
CN103298482B (zh) 2015-08-19
KR20190126189A (ko) 2019-11-08
WO2012058480A1 (en) 2012-05-03
US8969524B2 (en) 2015-03-03
TW201730205A (zh) 2017-09-01
EP2632479B1 (en) 2017-06-14
US20170267743A1 (en) 2017-09-21
BR112013010362A2 (pt) 2016-08-02
DK2632479T3 (en) 2017-08-07
PT2632479T (pt) 2017-07-24
KR20130128404A (ko) 2013-11-26
EP3260132A1 (en) 2017-12-27
JP2017095463A (ja) 2017-06-01
KR102040867B1 (ko) 2019-11-07
NZ609474A (en) 2015-06-26
ES2639039T3 (es) 2017-10-25
EP2632479A1 (en) 2013-09-04

Similar Documents

Publication Publication Date Title
US9512198B2 (en) FVIII peptides for immune tolerance induction and immunodiagnostics
KR102158225B1 (ko) 헬퍼 t세포의 활성화 방법
BR112019018616A2 (pt) peptídeos e métodos para o tratamento de diabetes
AU2012380681A1 (en) Novel melanoma antigen peptide and uses thereof
CN111944021A (zh) Cd47亲和肽及其应用
WO2007002811A2 (en) Methods and compositions for treating melanoma
JP6363996B2 (ja) 免疫原性が低下した凝固因子ｖｉｉｉ
HK1246211A1 (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1246211B (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954A (en) Fviii peptides for immune tolerance induction and immunodiagnostics
HK1188954B (en) Fviii peptides for immune tolerance induction and immunodiagnostics
EA043749B1 (ru) Пептиды фактора viii для индукции иммунной толерантности и иммунодиагностики

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees